Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

QR Code

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

Saved in:

Bibliographic Details
Main Authors:	Mary L Disis, John B Liao, Doreen M Higgins, Jennifer S Childs, Sasha E Stanton, Anna V Tinker, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Hania N Shakalia, Ron E Swensen, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Barbara A Goff
Format:	article
Language:	EN
Published:	BMJ Publishing Group 2021
Subjects:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/fa0344d0725b4c7788695fafcc3f18e8
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
by: Vamsidhar Velcheti, et al.
Published: (2021)

High grade serous ovarian carcinomas originate in the fallopian tube
by: S. Intidhar Labidi-Galy, et al.
Published: (2017)

The Role of Universities and Law Schools in Documenting Serious International Crimes and Advancing the Rule of Law
by: Brianne McGonigle Leyh
Published: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
by: Abdel Kader Y, et al.
Published: (2013)

Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells
by: Sweta Dash, et al.
Published: (2021)

Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients
by: Sasha E. Stanton, et al.
Published: (2021)

Hypertrophic lichenoid dermatitis during pembrolizumab treatment
by: Ryoma Honda, et al.
Published: (2021)

Nitric oxide is not involved in Neisseria gonorrhoeae-induced cellular damage of human Fallopian tubes in vitro
by: GARCÍA,KATHERINE P, et al.
Published: (2010)

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
by: Shuang Zhang, et al.
Published: (2019)

Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution
by: Thomas E. Bartlett, et al.
Published: (2016)

Perigeniculate arachnoid cysts and CSF fistulae of the fallopian canal: Histopathologic correlates of a rare clinical entity
by: Emerson E. Lee, et al.
Published: (2021)

Apoptosis related genes expressed in cultured Fallopian tube epithelial cells infected in vitro with Neisseria gonorrhoeae
by: REYES,PAZ A, et al.
Published: (2007)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
by: S. C. Sasson, et al.
Published: (2021)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
by: Stijn Moens, et al.
Published: (2021)

Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
by: V. La, et al.
Published: (2017)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
by: Bo Gao, et al.
Published: (2018)

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity
by: Sofia C. Nunes, et al.
Published: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
by: Miguel Martin, et al.
Published: (2021)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
by: Thomas M, et al.
Published: (2017)

Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell lines
by: Viscarra,Tamara, et al.
Published: (2019)

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
by: Mudad R, et al.
Published: (2017)

The chemotherapeutic drug carboplatin affects macrophage responses to LPS and LPS tolerance via epigenetic modifications
by: Atsadang Boonmee, et al.
Published: (2021)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
by: Sanju Cyriac, et al.
Published: (2021)

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
by: Anna E. Protasova, et al.
Published: (2021)

CT based radiomic approach on first line pembrolizumab in lung cancer
by: Marta Zerunian, et al.
Published: (2021)

Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs
by: Brittany L. Fowler, et al.
Published: (2021)

The Rule of Law from Below – A Concept Under Development
by: Antoine Buyse, et al.
Published: (2021)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
by: V. La, et al.
Published: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
by: Christine S Walsh, et al.
Published: (2021)

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
by: Giuseppe Giuffrida, et al.
Published: (2021)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
by: Lars Ny, et al.
Published: (2021)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
by: Hui Zheng, et al.
Published: (2021)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
by: Tanya E. Keenan, et al.
Published: (2021)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
by: Alexa C. Glencer, et al.
Published: (2021)

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
by: Tae‐Hun Kim, et al.
Published: (2021)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Somasundaram A, et al.
Published: (2017)

Recurrent outflow obstruction of a choked catheter for peritoneal dialysis caused by a fallopian tube fimbria in a five-month-old female
by: Ryoya Furugane, et al.
Published: (2022)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
by: Wu L, et al.
Published: (2021)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
by: Aya Yamashita, et al.
Published: (2021)

Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
by: Franziska Weiner, et al.
Published: (2021)